Trial Profile

An Open-Label Positron Emission Tomography Study to Investigate the Effect of Adjunctive Administration of SEP-363856 on Brain Dopamine Synthesis Capacity Using 18F-DOPA in Adult Subjects With Schizophrenia

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ulotaront (Primary)
Indications Schizophrenia
Focus Therapeutic Use
Sponsors Otsuka Pharmaceutical Development & Commercialization; Sumitomo Pharma America; Sunovion Pharmaceuticals

26 Jun 2023 Status changed from recruiting to completed.
08 Feb 2023 Planned End Date changed from 15 Jan 2023 to 15 Jun 2023.
08 Feb 2023 Planned primary completion date changed from 15 Jan 2023 to 15 Jun 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com